Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance.

Al-Malky, Hamdan S; Al Harthi, Sameer E; Osman, Abdel-Moneim M

Al-Malky, Hamdan S; Al Harthi, Sameer E; Osman, Abdel-Moneim M.

Affiliation

Al-Malky HS; Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Al Harthi SE; Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Osman AM; Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

J Oncol Pharm Pract ; 26(2): 434-444, 2020 Mar.

Article in En | MEDLINE | ID: mdl-31594518

Subject(s)

Antibiotics, Antineoplastic/adverse effects; Cardiotoxins/adverse effects; Cardiovascular Diseases/chemically induced; Doxorubicin/adverse effects; Drug Resistance, Neoplasm/drug effects; Neoplasms/drug therapy; Animals; Antibiotics, Antineoplastic/therapeutic use; Cardiotoxicity; Cardiotoxins/therapeutic use; Cardiovascular Diseases/diagnosis; Doxorubicin/therapeutic use; Drug Resistance, Neoplasm/physiology; Endothelium, Vascular/drug effects; Endothelium, Vascular/metabolism; Humans; Neoplasms/diagnosis

Key words

Doxorubicin; cancer; cardiotoxicity; multidrug resistance

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Doxorubicin / Drug Resistance, Neoplasm / Cardiotoxins / Antibiotics, Antineoplastic / Neoplasms Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2020 Document type: Article Affiliation country: Saudi Arabia Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google